In the FLOW trial, once-weekly semaglutide lowered major kidney disease events by 24% in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
A prespecified secondary analysis of the STEP-HFpEF programme found that once-weekly semaglutide 2.4 mg lowered NT-proBNP and produced larger symptom gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
A post hoc analysis of the SURPASS-2 phase 3 trial comparing tirzepatide and semaglutide on HOMA2 markers of beta-cell function and insulin sensitivity in type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of the SURPASS program found tirzepatide produced similar HbA1c, weight, and cardiometabolic improvements whether type 2 diabetes was diagnosed before or after age 40. PICO summary and expert commentary.
A published study protocol for a 52-week double-blind randomised trial of semaglutide plus empagliflozin versus each drug alone for NAFLD in type 2 diabetes. No efficacy results are reported yet. PICO summary and expert commentary.
Pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials of semaglutide 2.4 mg in obesity-related HFpEF, with PICO summary and expert commentary.
STEP-HFpEF DM: once-weekly semaglutide 2.4 mg improved symptoms, weight, and exercise capacity versus placebo in obese, diabetic patients with HFpEF. PICO summary and expert commentary.
A phase 2b trial of the GLP-1/glucagon receptor agonist cotadutide showed dose-dependent reductions in albuminuria in type 2 diabetes with CKD. PICO summary and expert commentary.
Design and baseline characteristics of the phase 3 ESSENCE trial of weekly semaglutide 2.4 mg in 800 participants with biopsy-proven MASH and fibrosis stage 2 or 3, with no efficacy results reported yet. PICO summary and expert commentary.
A single-center randomized controlled trial testing a cloud-hospital data platform plus dietary management against standard care in 180 adults with type 2 diabetes, reporting a modest 12-week HbA1c advantage. PICO summary and expert commentary.